-
#SITC19:$NKTR 214 +Nivo seems better than IPI +NIVO. Adds CRs (34% vs. 11%) and PFS (>18 months vs. 11.5) w less Gr3-4 TAEs (17% vs 55%); But ORR in PDL-1 neg was 39% (Nivo+214) vs. 55% (Ipi + Nivo). Overall better. http://bit.ly/Nivo_IPI_NEJM http://bit.ly/NKTR_SITC19 -
stuff I saw at
#SITC19 - the resurrection of IL2 (mhm) - a cautious Siglec15 reception - too many TLR7/8 posters - ditto cytokine x PD-L1 bispecific posters - a glimmer of hope for 4-1BB - THE MOST GORGEOUS IMAGING DATA -
My take on a few
#SITC19 presentations (yes, I'm puzzled by$NKTR ) via@Vantageanalysis http://bit.ly/32xHnYp$NXTC$PIRS$CYADPrikaži ovu nit -
$NXTC Siglec-15 data at#SITC19 http://ir.nextcure.com/static-files/eb4f4717-87f9-49d1-84d6-02762b85ffec … -No new responses in NSCLC -CR occurred in lowest 8mg dose - 0 response in 36 pts of other cancer types So is a CR for a 7.6mm lesion really worth >$1billion? Is a <10mm lesion even qualified as target lesion under RECIST?pic.twitter.com/VmuT8zxNkK
-
Are you brave enough to sit through
#SITC19 and get your body inked or just to watch people? Get your tickets now by going onto https://www.howler.co.za/sowetoinkfest pic.twitter.com/FHWkz3lmhB
-
Stopping IO early did not correlate with progression: those off ipi/nivo due to AE vs those who continued therapy with equal (maybe better) OS
@sitcancer Sparkathon resulting in randomized trial led by Thomas Marron and@RPatelMDPHD and collaboration with@eaonc trial#SITC19 pic.twitter.com/L1lr3KH3ft
-
Keep in mind that the best tattoo shop for the day wins a Motor Bike sponsored by Soweto Ink. So don’t miss out

#SITC#SITC19#SITC19#SITCpic.twitter.com/EzRJbwwbJM
Prikaži ovu nit -
Encouraging monotx data for a Siglec15 targeting therapeutic in Phase I. Could be the first clinically important checkpoint inhibitor in the post-PDL1/PD1 world? Single agent activity, irAEs and anti-correlation with PDL1 expression are particularly interesting.
#SITC19#SITC2019pic.twitter.com/fCEOXDU16S
-
Timely update on trends in clinical development for PD-1/PD-L1 inhibitors into
#SITC19 from@CancerResearch https://www.nature.com/articles/d41573-019-00182-w … Interesting data point on fast recruitment rate for cancer trials in China (for those wondering about why$AMGN did$BGNE deal on the dev side)pic.twitter.com/kXeAW1Y90C
-
Dr. Thomas Marron presenting an update of our SITC Sparkathon team project.
@sitcancerECS#SITC19 pic.twitter.com/kooopyoZg2
-
#SITC19 finally made it here and excited to learn. Can we PLEASE have some trials for checkpoint resistant melanoma. I have a lot of patients. And make some prior immuno tox allowed! -
Italian medical oncologists from
@DanaFarber at@sitcancer@sitcancerECS#SITC19@BiagioMd@GLambertiMD@DrChoueiri@DrMarkAwadpic.twitter.com/WrOywyL3xL
-
We will be at
#SITC19 this weekend to present data showing how our CRISPRomics discovery engine can point the direction towards promising avenues of#drugdevelopment https://www.sitcancer.org/2019/home -
Not so fast on
$NXTC this#sitc19 presentation is a major let down vs abstract. No new responders. CR was at lowest dose. Both responders not markered for s15 levels. PK not clean. Total of 49 patients across indications and 2 responses does not justify the stock at these levels. pic.twitter.com/1JcsqrtD4p
-
Viyara Matson from Tom Gajewskis group is giving a fantastic talk on their work showing the importance of the microbiome on shaping the immune repertoire. Impressive single cell data showing key changes within the myeloid compartment
#SITC19#sitcpic.twitter.com/6Fo0Qc5wcH
Prikaži ovu nit -
@abbyrartistry it was incredible to meet Abby and her sister Charlotte at@sitc 2019 in#NECBirmingham@thenec#makeup#SITC2019#sitc19#inspiringvanessa
pic.twitter.com/6u8d78SRiZ – mjesto: NEC Atrium
Prikaži ovu nit -
Fascinating insights - for me at least. Many of the non mutated tumor antigens are in fact expressed in the context of inflammation = broad disease associated antigens. Universal vaccines ? Dr. Finn
@sitcancer#SITC19 pic.twitter.com/oYGKREl6kf
-
Fantastic talk by Giuseppe Lamberti
@GLambertiMD at#SITC19 on genomic correlates of PD-L1 expression in NSCLC!@DanaFarberpic.twitter.com/Tjp0N5qySI
-
$NXTC +37% --> Biggest winner for#SITC19 abstracts release Single agent activity in NSCLC: BORR: 2/7 or 29%, DCR: 5/7 or 71% 1 CR (ongoing at 41 weeks) 1 PR (ongoing at 14 weeks) Siglec-15 mAb the next hot sexy thing in#immunotherapy race? pic.twitter.com/xJg6ht4EE4
-
Pleased to present our poster outlining positive new findings for our Lead Immunocytokine Program KY1043 at
#SITC2019#SITC19 https://tinyurl.com/yxkzsa54 pic.twitter.com/3fo3Pc4fXB
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.